Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization. As Chief Business Officer, Dr. Beauparlant is responsible for the development and execution of business strategy for Diazon.
Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities.
Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant is also Chief Business Officer at Therillia.
Dr. Beauparlant holds a Ph.D. from McGill University.
Michael Dixon, has over 18 years’ experience working in an executive role for venture-backed companies.
Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.
Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon is also president and chief executive officer at Therillia Development Company.
Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.
Louise Proulx is an industry veteran with 30 years’ experience in the pharmaceutical industry and has held scientific and managerial positions of increasing responsibilities. Notably, Dr. Proulx was Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice Principal Research at McGill University. She has been Vice President, Product Development at ViroChem Pharma Inc. and Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals. Dr. Proulx is also chief development officer at Therillia Development Company.
Dr. Proulx has been a member of several boards of directors and is a member of the board of directors of the Research Institute of McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors. She is also member of the Canada Foundation for Innovation.
Dr. Proulx holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm.
Gordon Shore, a Professor of Biochemistry and Oncology and member of the Rosalind and Morris Goodman Cancer Research Centre of McGill University, is internationally recognized for his research on cell survival and death mechanisms. Dr. Shore is also chief scientific officer at Therillia Development Company.
In 1998, he leveraged this research and co-founded Gemin X Pharmaceuticals Inc. and was a Director and its chief scientific officer until 2011 when it was acquired by Cephalon (now Teva). He was also interim CEO (2007/8). During his tenure with the company, Gemin X advanced two novel, targeted small molecule drug candidates from concept, through discovery and into late stage clinical development in oncology. He focused additional research efforts both at Gemin X and at McGill to elucidate rational paths to clinical proof of concept studies for these agents.
In 2010, Dr. Shore, together with his colleague Dr. Anne Roulston, extended such research at McGill, winning grants to build an Integrated Functional Genomics Platform that conducts genome-wide approaches focused on synthetic lethality and personalized medicine. The goal of this Integrated Platform is to generate the knowledge and tools to elucidate a clinical path forward for new targeted agents, especially in, but not limited to, oncology.